Recent Additions

This page includes the documents that were newly added to the repository within the last 30 days.

All these words:

This exact word or phrase:

Any of these words:

None of these words:

Language:

Visit our Help Page for additional assistance

Select a Range:

Select a Format:

Custom Search Builder:

Custom Search Box

Visit our Help Page for additional assistance

Showing 281 - 300 of 1970 results

Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel.

Fowlkes, Ashley L. ;

Peretz, Alon

December 2024 | International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 2024, v. 149

Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previ ...

10/10/2026

Supporting Files

Title : Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel. Personal Author(s) : Fowlkes, Ashley L.;Peretz, Alon;Greenberg, David;Hirsch, Avital;Martin, Emily T.;Levine, Min Z.;Edwards, Laura;Radke, Sarah;Lauring, Adam S.;Ferdinands, Jill M.;Zhang, Chao;Yoo, Young M.;Dreiher, Jacob;Newes-Adeyi, Gabriella;Azziz-Baumgartner, Eduardo;Fry, Alicia M.;Monto, Arnold S.;Balicer, Ran;Thompson, Mark G.;Katz, Mark A.; Published Date : December 2024 Pages in Document : 107260 (21 pdf pages) Source : International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 2024, v. 149 DOI : https://doi.org/10.1016/j.ijid.2024.107260 Journal Title : International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Fowlkes, A. L., Peretz, A., Greenberg, D., Hirsch, A., Martin, E. T., Levine, M. Z., Edwards, L., Radke, S., Lauring, A. S., Ferdinands, J. M., Zhang, C., Yoo, Y. M., Dreiher, J., Newes-Adeyi, G., Azziz-Baumgartner, E., Fry, A. M., Monto, A. S., Balicer, R., Thompson, M. G., & Katz, M. A. (2024). Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 149. https://doi.org/10.1016/j.ijid.2024.107260

Fowlkes, Ashley L., Alon Peretz, David Greenberg, Avital Hirsch, Emily T. Martin, Min Z. Levine, and Laura Edwards, et al.. "Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 149 (2024). https://doi.org/10.1016/j.ijid.2024.107260.

Fowlkes, Ashley L., et al. "Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 149, 2024. Stacks. https://doi.org/10.1016/j.ijid.2024.107260.
Export RIS Citation Information. TY - Journal Article AU - Fowlkes, Ashley L. AU - Peretz, Alon AU - Greenberg, David AU - Hirsch, Avital AU - Martin, Emily T. AU - Levine, Min Z. AU - Edwards, Laura AU - Radke, Sarah AU - Lauring, Adam S. AU - Ferdinands, Jill M. AU - Zhang, Chao AU - Yoo, Young M. AU - Dreiher, Jacob AU - Newes-Adeyi, Gabriella AU - Azziz-Baumgartner, Eduardo AU - Fry, Alicia M. AU - Monto, Arnold S. AU - Balicer, Ran AU - Thompson, Mark G. AU - Katz, Mark A. AB - Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants. AB - From October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titres against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titre (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 vs ≤2). AB - Among 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval [CI] 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titres than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0). AB - RIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4. AB - NCT04523324. AB - Author manuscript AN - cdc:261987 C4 - PMC11883642 DO - https://doi.org/10.1016/j.ijid.2024.107260 J2 - International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases KW - Influenza A Virus, H1N1 Subtype KW - Female KW - Influenza B virus KW - Vaccination KW - Prospective Studies KW - Young Adult KW - Health Personnel KW - Influenza Vaccines KW - Immunogenicity, Vaccine KW - Vaccines, Inactivated KW - Vaccines, Synthetic KW - Vaccine Efficacy KW - Antibodies, Viral KW - Male KW - Influenza A Virus, H3N2 Subtype KW - Humans KW - Middle Aged KW - Hemagglutination Inhibition Tests KW - Adult KW - Influenza, Human KW - Influenza vaccine KW - Recombinant KW - Immunogenicity KW - Healthcare personnel KW - Flublok KW - Humans KW - Influenza Vaccines KW - Health Personnel KW - Female KW - Adult KW - Influenza, Human KW - Male KW - Antibodies, Viral KW - Middle Aged KW - Vaccines, Synthetic KW - Immunogenicity, Vaccine KW - Prospective Studies KW - Vaccination KW - Vaccines, Inactivated KW - Influenza A Virus, H1N1 Subtype KW - Influenza B virus KW - Influenza A Virus, H3N2 Subtype KW - Hemagglutination Inhibition Tests KW - Young Adult KW - Vaccine Efficacy LA - eng PY - 2024 T2 - International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases T2 - International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 2024, v. 149 TI - Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel. VL - 149 UR - https://stacks.cdc.gov/view/cdc/261987 ER -
Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: a Study From Lupus Midwest Network (LUMEN).

Sanchez-Rodriguez, Alain ;

Meade-Aguilar, Jose Antonio

April 2025 | Arthritis Care & Research, 2025, v. 77, no. 4

We aimed to characterize presentation and care pathways of patients with systemic lupus erythematosus (SLE), and delays in access to SLE-specialized care.We included patients with incident SLE from the Lupus Midwest Network registry. Time from the first medical encounter for SLE clinical manifestation to access to SLE-specialized care, physician di ...

10/10/2026

Supporting Files

Title : Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: a Study From Lupus Midwest Network (LUMEN). Personal Author(s) : Sanchez-Rodriguez, Alain;Meade-Aguilar, Jose Antonio;Yang, Jeffrey X.;Figueroa-Parra, Gabriel;Hanson, Andrew C.;Langenfeld, Hannah E.;Thanarajasingam, Uma;Chamberlain, Alanna M.;Greenlund, Kurt J.;Barbour, Kamil E.;Crowson, Cynthia S.;Duarte-García, Alí; Published Date : April 2025 Pages in Document : 451-459 (18 pdf pages) Source : Arthritis Care & Research, 2025, v. 77, no. 4 DOI : https://doi.org/10.1002/acr.25445 Journal Title : Arthritis Care & Research
Sanchez-Rodriguez, A., Meade-Aguilar, J. A., Yang, J. X., Figueroa-Parra, G., Hanson, A. C., Langenfeld, H. E., Thanarajasingam, U., Chamberlain, A. M., Greenlund, K. J., Barbour, K. E., Crowson, C. S., & Duarte-García, A. (2025). Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: a Study From Lupus Midwest Network (LUMEN). Arthritis Care & Research, 77(4). https://doi.org/10.1002/acr.25445

Sanchez-Rodriguez, Alain, Jose Antonio Meade-Aguilar, Jeffrey X. Yang, Gabriel Figueroa-Parra, Andrew C. Hanson, Hannah E. Langenfeld, and Uma Thanarajasingam, et al.. "Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: a Study From Lupus Midwest Network (LUMEN)." Arthritis Care & Research 77, no. 4 (2025). https://doi.org/10.1002/acr.25445.

Sanchez-Rodriguez, Alain, et al. "Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: a Study From Lupus Midwest Network (LUMEN)." Arthritis Care & Research, vol. 77, no. 4, 2025. Stacks. https://doi.org/10.1002/acr.25445.
Export RIS Citation Information. TY - Journal Article AU - Sanchez-Rodriguez, Alain AU - Meade-Aguilar, Jose Antonio AU - Yang, Jeffrey X. AU - Figueroa-Parra, Gabriel AU - Hanson, Andrew C. AU - Langenfeld, Hannah E. AU - Thanarajasingam, Uma AU - Chamberlain, Alanna M. AU - Greenlund, Kurt J. AU - Barbour, Kamil E. AU - Crowson, Cynthia S. AU - Duarte-García, Alí AB - We aimed to characterize presentation and care pathways of patients with systemic lupus erythematosus (SLE), and delays in access to SLE-specialized care. AB - We included patients with incident SLE from the Lupus Midwest Network registry. Time from the first medical encounter for SLE clinical manifestation to access to SLE-specialized care, physician diagnosis, and treatment was estimated. Delays were defined as ≥6 months to access specialized care. We compared SLE manifestations, disease activity, and Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage indexes (SDI) between patients with and without delays. Logistic regression models assessed associations with delays. AB - The study included 373 patients with SLE. The median time to access SLE-specialized care was 1.1 (95% confidence interval [CI] 0.9-1.5) months, time to diagnosis was 30.6 (95% CI 18.9-48.1) months, and time to treatment initiation was 4.7 (95% CI 3.9-8.4) months. Approximately 25% of patients (93 out of 373) experienced delays accessing specialized care, which were associated with fewer SLE manifestations at first SLE-related encounter (fewer than two SLE domains; 92% vs 72%, P < 0.001). Patients with mucocutaneous or musculoskeletal manifestations were less likely to experience delays, whereas hematologic (odds ratio [OR] 1.71, 95% CI 1.03-2.84) or antiphospholipid antibodies domains (OR 6.05, 95% CI 2.46-14.88) were associated with delays. Delays were associated with damage at first access to SLE-specialized care (SDI ≥1; 30% vs 7%, P < 0.001). AB - Patients follow a heterogeneous pathway to receive care. One-fourth of patients experienced delays accessing SLE-specialized care, which was associated with disease-related damage. Fewer manifestations, hematologic manifestations, or antiphospholipid antibodies were associated with delays. AB - Author manuscript AN - cdc:261986 C4 - PMC13215449 DO - https://doi.org/10.1002/acr.25445 IS - 4 J2 - Arthritis Care & Research KW - Time-to-Treatment KW - Female KW - Critical Pathways KW - Lupus Erythematosus, Systemic KW - Male KW - Humans KW - Registries KW - Middle Aged KW - Health Services Accessibility KW - Young Adult KW - Time Factors KW - Adult KW - Systemic lupus erythematosus KW - healthcare access KW - diagnostic delays KW - specialized care KW - Humans KW - Lupus Erythematosus, Systemic KW - Female KW - Male KW - Adult KW - Middle Aged KW - Time-to-Treatment KW - Health Services Accessibility KW - Registries KW - Time Factors KW - Young Adult KW - Critical Pathways LA - eng PY - 2025 T2 - Arthritis Care & Research T2 - Arthritis Care & Research, 2025, v. 77, no. 4 TI - Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: a Study From Lupus Midwest Network (LUMEN). VL - 77 UR - https://stacks.cdc.gov/view/cdc/261986 ER -
Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.

Baliashvili, Davit ;

Merabishvili, Tsira

April 2025 | Journal of Viral Hepatitis, 2025, v. 32, no. 4

Exposure to healthcare procedures might be a source of hepatitis C virus (HCV) transmission in Georgia, one of the few countries currently on track to eliminate hepatitis C. While there has been a history of iatrogenic transmission of HCV, the risk of HCV transmission related to endoscopic procedures has not been previously assessed in Georgia. The ...

10/10/2026

Supporting Files

Title : Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia. Personal Author(s) : Baliashvili, Davit;Merabishvili, Tsira;Tskhomelidze, Irina;Tsereteli, Maia;Karichashvili, Lika;Chitadze, Nazi;Armstrong, Paige A.;Butsashvili, Maia; Published Date : April 2025 Pages in Document : e14022 (7 pdf pages) Source : Journal of Viral Hepatitis, 2025, v. 32, no. 4 DOI : https://doi.org/10.1111/jvh.14022 Journal Title : Journal of Viral Hepatitis
Baliashvili, D., Merabishvili, T., Tskhomelidze, I., Tsereteli, M., Karichashvili, L., Chitadze, N., Armstrong, P. A., & Butsashvili, M. (2025). Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia. Journal of Viral Hepatitis, 32(4). https://doi.org/10.1111/jvh.14022

Baliashvili, Davit, Tsira Merabishvili, Irina Tskhomelidze, Maia Tsereteli, Lika Karichashvili, Nazi Chitadze, Paige A. Armstrong, and Maia Butsashvili. "Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia." Journal of Viral Hepatitis 32, no. 4 (2025). https://doi.org/10.1111/jvh.14022.

Baliashvili, Davit, et al. "Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia." Journal of Viral Hepatitis, vol. 32, no. 4, 2025. Stacks. https://doi.org/10.1111/jvh.14022.
Export RIS Citation Information. TY - Journal Article AU - Baliashvili, Davit AU - Merabishvili, Tsira AU - Tskhomelidze, Irina AU - Tsereteli, Maia AU - Karichashvili, Lika AU - Chitadze, Nazi AU - Armstrong, Paige A. AU - Butsashvili, Maia AB - Exposure to healthcare procedures might be a source of hepatitis C virus (HCV) transmission in Georgia, one of the few countries currently on track to eliminate hepatitis C. While there has been a history of iatrogenic transmission of HCV, the risk of HCV transmission related to endoscopic procedures has not been previously assessed in Georgia. The goal of this study was to assess HCV seroconversion among individuals undergoing endoscopic procedures to estimate the relative role and incidence of HCV infection attributable to endoscopic procedures. A prospective cohort study was conducted in four endoscopy units in two cities (Tbilisi and Kutaisi) of Georgia during April-September, 2021. Recruitment of study participants was conducted using convenience sampling, and every eligible patient was approached and invited to participate in the study. Study population included adults (age ≥ 18 years) who received an endoscopic procedure (gastroscopy, colonoscopy and bronchoscopy) in inpatient or outpatient unit at the study sites. HCV antibody (anti-HCV) testing was conducted using rapid diagnostic test (RDT) on the same day they underwent the endoscopic procedure. Patients with a non-reactive anti-HCV baseline test were retested after 6 months. Patients with reactive baseline tests were excluded from the study and linked to further testing and care. Participants with a reactive result on follow-up RDTs were retested using a lab-based anti-HCV and HCV ribonucleic acid (RNA) test. A total of 981 HCV antibody non-reactive participants were enrolled; 590 (64.8%) of them were reached and retested after 6 months. At retesting, two out of 590 (0.3%) individuals had a reactive anti-HCV result on RDT and both were negative on laboratory-based anti-HCV and HCV RNA tests. Based on the results of this study, endoscopic procedures were not shown to contribute to HCV transmission in Georgia. AB - Author manuscript AN - cdc:261985 C4 - PMC11885007 DO - https://doi.org/10.1111/jvh.14022 IS - 4 J2 - Journal of Viral Hepatitis KW - Female KW - Endoscopy KW - Prospective Studies KW - Aged KW - Young Adult KW - Hepatitis C KW - Incidence KW - Male KW - Hepatitis C Antibodies KW - Middle Aged KW - Humans KW - Adult KW - Georgia (Republic) KW - Hepacivirus KW - endoscopy KW - HCV KW - hepatitis C KW - transmission KW - Humans KW - Male KW - Female KW - Hepatitis C KW - Prospective Studies KW - Middle Aged KW - Georgia (Republic) KW - Adult KW - Endoscopy KW - Hepatitis C Antibodies KW - Aged KW - Incidence KW - Hepacivirus KW - Young Adult LA - eng PY - 2025 T2 - Journal of Viral Hepatitis T2 - Journal of Viral Hepatitis, 2025, v. 32, no. 4 TI - Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia. VL - 32 UR - https://stacks.cdc.gov/view/cdc/261985 ER -
Limitations in Activities of Daily Living Among Individuals With Systemic Lupus Erythematosus.

Plantinga, Laura C. ;

Bowling, C. Barrett

April 2025 | Arthritis Care & Research, 2025, v. 77, no. 4

We aimed to estimate the burden and identify potential correlates of limitations in activities of daily living (ADLs) among persons with systemic lupus erythematosus (SLE).Individuals with SLE were recruited from a population-based cohort (October 2019 to May 2022) and reported their ability to independently perform various instrumental ADLs (IADLs ...

10/10/2026

Supporting Files

Title : Limitations in Activities of Daily Living Among Individuals With Systemic Lupus Erythematosus. Personal Author(s) : Plantinga, Laura C.;Bowling, C. Barrett;Pearce, Bradley D.;Hoge, Courtney;Dunlop-Thomas, Charmayne;Lim, S. Sam;Katz, Patricia P.;Yazdany, Jinoos; Published Date : April 2025 Pages in Document : 440-450 (21 pdf pages) Source : Arthritis Care & Research, 2025, v. 77, no. 4 DOI : https://doi.org/10.1002/acr.25446 Journal Title : Arthritis Care & Research
Plantinga, L. C., Bowling, C. B., Pearce, B. D., Hoge, C., Dunlop-Thomas, C., Lim, S. S., Katz, P. P., & Yazdany, J. (2025). Limitations in Activities of Daily Living Among Individuals With Systemic Lupus Erythematosus. Arthritis Care & Research, 77(4). https://doi.org/10.1002/acr.25446

Plantinga, Laura C., C. Barrett Bowling, Bradley D. Pearce, Courtney Hoge, Charmayne Dunlop-Thomas, S. Sam Lim, Patricia P. Katz, and Jinoos Yazdany. "Limitations in Activities of Daily Living Among Individuals With Systemic Lupus Erythematosus." Arthritis Care & Research 77, no. 4 (2025). https://doi.org/10.1002/acr.25446.

Plantinga, Laura C., et al. "Limitations in Activities of Daily Living Among Individuals With Systemic Lupus Erythematosus." Arthritis Care & Research, vol. 77, no. 4, 2025. Stacks. https://doi.org/10.1002/acr.25446.
Export RIS Citation Information. TY - Journal Article AU - Plantinga, Laura C. AU - Bowling, C. Barrett AU - Pearce, Bradley D. AU - Hoge, Courtney AU - Dunlop-Thomas, Charmayne AU - Lim, S. Sam AU - Katz, Patricia P. AU - Yazdany, Jinoos AB - We aimed to estimate the burden and identify potential correlates of limitations in activities of daily living (ADLs) among persons with systemic lupus erythematosus (SLE). AB - Individuals with SLE were recruited from a population-based cohort (October 2019 to May 2022) and reported their ability to independently perform various instrumental ADLs (IADLs) and basic ADLs (BADLs) via survey. Limitations were defined as having at least some difficulty performing at least one of the IADLs or BADLs. Descriptive statistics were calculated, and associations (adjusted odds ratios [aORs]) of various participant characteristics with IADL and BADL limitations were assessed with logistic regression adjusting for age, sex, and race. AB - The mean age of the 436 participants was 46.2 years; most were female (91.7%) and Black (82.8%). More than half (56.2%) reported limitations in IADLs, most commonly housekeeping (50.7%), laundry (37.2%), and shopping (33.0%); 43.8% reported limitations in independently performing BADLs, most commonly transferring (26.6%), bathing (25.3%), dressing (24.4%), and continence (22.0%). Higher disease activity (greater than or equal to vs less than the median) was strongly associated with IADLs (aOR 6.49, 95% confidence interval [CI] 4.15-10.2) and BADLs (aOR 7.35, 95% CI 4.70-11.5), along with higher depression and perceived stress scores, lower educational attainment and income, and older age. AB - IADL and BADL limitations may be common in individuals with SLE and more prevalent among those who report higher disease activity, depressive symptoms, and lower income and among those who are older. Research to support evidence-based strategies for improvement in quality of life and maintenance of independence in the older SLE population is warranted. AB - Author manuscript AN - cdc:261984 C4 - PMC11932797 DO - https://doi.org/10.1002/acr.25446 IS - 4 J2 - Arthritis Care & Research KW - Cross-Sectional Studies KW - Female KW - Lupus Erythematosus, Systemic KW - Quality of Life KW - Aged KW - Male KW - Humans KW - Middle Aged KW - Activities of Daily Living KW - Adult KW - Humans KW - Lupus Erythematosus, Systemic KW - Activities of Daily Living KW - Female KW - Male KW - Middle Aged KW - Adult KW - Cross-Sectional Studies KW - Aged KW - Quality of Life LA - eng PY - 2025 T2 - Arthritis Care & Research T2 - Arthritis Care & Research, 2025, v. 77, no. 4 TI - Limitations in Activities of Daily Living Among Individuals With Systemic Lupus Erythematosus. VL - 77 UR - https://stacks.cdc.gov/view/cdc/261984 ER -
IFISH6: Successes and Lessons For the Future.

Milkovich, Pamela J. ;

Roome, Amanda B.

April 2025 | Journal of Agromedicine, 2025, v. 30, no. 2

The IFISH6 conference brought together researchers and practitioners from around the world to discuss innovations and progress in protecting the safety and health of workers in the fishing, aquaculture, and seafood processing industries. This brief provides an overview of the feedback that was received about this conference, ideas for enhancing the ...

10/10/2026

Supporting Files

Title : IFISH6: Successes and Lessons For the Future. Personal Author(s) : Milkovich, Pamela J.;Roome, Amanda B.;Sorensen, Julie A.; Published Date : April 2025 Pages in Document : 207-209 (4 pdf pages) Source : Journal of Agromedicine, 2025, v. 30, no. 2 DOI : https://doi.org/10.1080/1059924X.2024.2413444 Journal Title : Journal of Agromedicine
Milkovich, P. J., Roome, A. B., & Sorensen, J. A. (2025). IFISH6: Successes and Lessons For the Future. Journal of Agromedicine, 30(2). https://doi.org/10.1080/1059924X.2024.2413444

Milkovich, Pamela J., Amanda B. Roome, and Julie A. Sorensen. "IFISH6: Successes and Lessons For the Future." Journal of Agromedicine 30, no. 2 (2025). https://doi.org/10.1080/1059924X.2024.2413444.

Milkovich, Pamela J., et al. "IFISH6: Successes and Lessons For the Future." Journal of Agromedicine, vol. 30, no. 2, 2025. Stacks. https://doi.org/10.1080/1059924X.2024.2413444.
Export RIS Citation Information. TY - Journal Article AU - Milkovich, Pamela J. AU - Roome, Amanda B. AU - Sorensen, Julie A. AB - The IFISH6 conference brought together researchers and practitioners from around the world to discuss innovations and progress in protecting the safety and health of workers in the fishing, aquaculture, and seafood processing industries. This brief provides an overview of the feedback that was received about this conference, ideas for enhancing the impact of IFISH7, and methods of continuing collaboration and innovation in between. AB - Author manuscript AN - cdc:261983 C4 - PMC13088492 DO - https://doi.org/10.1080/1059924X.2024.2413444 IS - 2 J2 - Journal of Agromedicine KW - Food-Processing Industry KW - Aquaculture KW - Humans KW - Occupational Health KW - Congresses as Topic KW - Evaluation KW - collaboration KW - Humans KW - Occupational Health KW - Aquaculture KW - Congresses as Topic KW - Food-Processing Industry LA - eng PY - 2025 T2 - Journal of Agromedicine T2 - Journal of Agromedicine, 2025, v. 30, no. 2 TI - IFISH6: Successes and Lessons For the Future. VL - 30 UR - https://stacks.cdc.gov/view/cdc/261983 ER -
Essential(ly Forgotten) Workers: Latine Youth Farmworkers During the COVID-19 Pandemic.

Arnold, Taylor J. ;

Morrison, Sharon D.

December 2024 | American Journal of Industrial Medicine, 2024, v. 67, no. 12

Essential workers across multiple industries faced a disproportionate burden of morbidity and mortality during the COVID-19 pandemic. The effects were especially severe for agricultural and food processing workers, many of whom are members of the structurally vulnerable Latine community. Under current U.S. federal laws, children under 12 years old ...

10/10/2026

Supporting Files

Title : Essential(ly Forgotten) Workers: Latine Youth Farmworkers During the COVID-19 Pandemic. Personal Author(s) : Arnold, Taylor J.;Morrison, Sharon D.;Martin Romero, Michelle Y.;Echeverria, Sandra E.;Zapata, Sylvia;Quandt, Sara A.;Torres-Lara, Fabiola;Robles Arvizu, Jose A;Arcury, Thomas A.; Published Date : December 2024 Pages in Document : 1121-1134 (24 pdf pages) Source : American Journal of Industrial Medicine, 2024, v. 67, no. 12 DOI : https://doi.org/10.1002/ajim.23671 Journal Title : American Journal of Industrial Medicine
Arnold, T. J., Morrison, S. D., Martin Romero, M. Y., Echeverria, S. E., Zapata, S., Quandt, S. A., Torres-Lara, F., Robles Arvizu, J. A., & Arcury, T. A. (2024). Essential(ly Forgotten) Workers: Latine Youth Farmworkers During the COVID-19 Pandemic. American Journal of Industrial Medicine, 67(12). https://doi.org/10.1002/ajim.23671

Arnold, Taylor J., Sharon D. Morrison, Michelle Y. Martin Romero, Sandra E. Echeverria, Sylvia Zapata, Sara A. Quandt, Fabiola Torres-Lara, Jose A Robles Arvizu, and Thomas A. Arcury. "Essential(ly Forgotten) Workers: Latine Youth Farmworkers During the COVID-19 Pandemic." American Journal of Industrial Medicine 67, no. 12 (2024). https://doi.org/10.1002/ajim.23671.

Arnold, Taylor J., et al. "Essential(ly Forgotten) Workers: Latine Youth Farmworkers During the COVID-19 Pandemic." American Journal of Industrial Medicine, vol. 67, no. 12, 2024. Stacks. https://doi.org/10.1002/ajim.23671.
Export RIS Citation Information. TY - Journal Article AU - Arnold, Taylor J. AU - Morrison, Sharon D. AU - Martin Romero, Michelle Y. AU - Echeverria, Sandra E. AU - Zapata, Sylvia AU - Quandt, Sara A. AU - Torres-Lara, Fabiola AU - Robles Arvizu, Jose A AU - Arcury, Thomas A. AB - Essential workers across multiple industries faced a disproportionate burden of morbidity and mortality during the COVID-19 pandemic. The effects were especially severe for agricultural and food processing workers, many of whom are members of the structurally vulnerable Latine community. Under current U.S. federal laws, children under 12 years old can legally work in agriculture, one of the most hazardous U.S. industries. Many of these working youth are Latine and experience health and educational inequities. AB - Using a community-based participatory research approach and a qualitative design, we conducted semi-structured in-depth interviews in North Carolina in 2022, with service providers in health, education, and advocacy fields (n = 10) and Latine youth farmworkers aged 10-17 (n = 24). We used participatory qualitative analysis methods and a reflexive thematic analysis to understand and describe the work experiences of these youth during the first 2 years of the pandemic. AB - Amidst precarious economic and school situations exacerbated by the COVID-19 pandemic, many youths described an increased need to work to support their families. While aware and sometimes fearful of the added occupational health risks of COVID-19, youth and their families felt they had few other options. Service providers and youth described minimal employer-provided safety protocols or equipment, yet some workers organized their own attempts at safety protocols. Youth narratives imply limited knowledge of basic workplace safety requirements. AB - Study findings emphasize the urgent need to address structural vulnerabilities shaping workplace policies and norms to protect Latine youth farmworkers to support their healthy development. AB - Author manuscript AN - cdc:261982 C4 - PMC11804972 DO - https://doi.org/10.1002/ajim.23671 IS - 12 J2 - American Journal of Industrial Medicine KW - Adolescent KW - Female KW - Farmers KW - Pandemics KW - Qualitative Research KW - SARS-CoV-2 KW - COVID-19 KW - Interviews as Topic KW - Occupational Health KW - Community-Based Participatory Research KW - Child KW - Male KW - Humans KW - Latino/Hispanic KW - youth farmworkers KW - essential workers KW - COVID-19 KW - occupational safety and health KW - child labor KW - health equity KW - agricultural health KW - Humans KW - COVID-19 KW - Adolescent KW - Farmers KW - Female KW - Male KW - Child KW - Community-Based Participatory Research KW - Qualitative Research KW - SARS-CoV-2 KW - Occupational Health KW - Interviews as Topic KW - Pandemics LA - eng PY - 2024 T2 - American Journal of Industrial Medicine T2 - American Journal of Industrial Medicine, 2024, v. 67, no. 12 TI - Essential(ly Forgotten) Workers: Latine Youth Farmworkers During the COVID-19 Pandemic. VL - 67 UR - https://stacks.cdc.gov/view/cdc/261982 ER -
T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.

Cho, Nam Woo ;

Guldberg, Sophia M.

February 2025 | Cancer Immunology Research, 2025, v. 13, no. 2

Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant t ...

10/10/2026

Supporting Files

Title : T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation. Personal Author(s) : Cho, Nam Woo;Guldberg, Sophia M.;Nabet, Barzin Y.;Yu, Jie Zeng;Kim, Eun Ji;Hiam-Galvez, Kamir J.;Yee, Jacqueline L.;DeBarge, Rachel;Tenvooren, Iliana;Ashitey, Naa Asheley;Lynce, Filipa;Dillon, Deborah A.;Rosenbluth, Jennifer M.;Spitzer, Matthew H.; Published Date : February 2025 Pages in Document : 229-244 (36 pdf pages) Source : Cancer Immunology Research, 2025, v. 13, no. 2 DOI : https://doi.org/10.1158/2326-6066.CIR-24-0416 Journal Title : Cancer Immunology Research
Cho, N. W., Guldberg, S. M., Nabet, B. Y., Yu, J. Z., Kim, E. J., Hiam-Galvez, K. J., Yee, J. L., DeBarge, R., Tenvooren, I., Ashitey, N. A., Lynce, F., Dillon, D. A., Rosenbluth, J. M., & Spitzer, M. H. (2025). T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation. Cancer Immunology Research, 13(2). https://doi.org/10.1158/2326-6066.CIR-24-0416

Cho, Nam Woo, Sophia M. Guldberg, Barzin Y. Nabet, Jie Zeng Yu, Eun Ji Kim, Kamir J. Hiam-Galvez, and Jacqueline L. Yee, et al.. "T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation." Cancer Immunology Research 13, no. 2 (2025). https://doi.org/10.1158/2326-6066.CIR-24-0416.

Cho, Nam Woo, et al. "T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation." Cancer Immunology Research, vol. 13, no. 2, 2025. Stacks. https://doi.org/10.1158/2326-6066.CIR-24-0416.
Export RIS Citation Information. TY - Journal Article AU - Cho, Nam Woo AU - Guldberg, Sophia M. AU - Nabet, Barzin Y. AU - Yu, Jie Zeng AU - Kim, Eun Ji AU - Hiam-Galvez, Kamir J. AU - Yee, Jacqueline L. AU - DeBarge, Rachel AU - Tenvooren, Iliana AU - Ashitey, Naa Asheley AU - Lynce, Filipa AU - Dillon, Deborah A. AU - Rosenbluth, Jennifer M. AU - Spitzer, Matthew H. AB - Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications. AB - Author manuscript AN - cdc:261981 C4 - PMC11790381 DO - https://doi.org/10.1158/2326-6066.CIR-24-0416 IS - 2 J2 - Cancer Immunology Research KW - Interleukin-1 KW - Female KW - Animals KW - Cell Line, Tumor KW - Tumor Microenvironment KW - Mice, Inbred C57BL KW - Inflammation KW - Drug Resistance, Neoplasm KW - Neoplasms KW - Tumor Necrosis Factor-alpha KW - Immune Checkpoint Inhibitors KW - Humans KW - T-Lymphocytes KW - Mice KW - Cancer Immunotherapy KW - Immune Checkpoint Inhibitors KW - Immunotherapy Resistance KW - MDSCs KW - IL-1 Receptor Signaling in Cancer KW - TNFα Signaling KW - NF-kB Signaling KW - T cell-mediated Immunosuppression KW - Immune Checkpoint Inhibitors KW - Tumor Necrosis Factor-alpha KW - Humans KW - Drug Resistance, Neoplasm KW - Animals KW - Interleukin-1 KW - Mice KW - T-Lymphocytes KW - Inflammation KW - Tumor Microenvironment KW - Neoplasms KW - Cell Line, Tumor KW - Female KW - Mice, Inbred C57BL LA - eng PY - 2025 T2 - Cancer Immunology Research T2 - Cancer Immunology Research, 2025, v. 13, no. 2 TI - T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation. VL - 13 UR - https://stacks.cdc.gov/view/cdc/261981 ER -
The Use of the CDC Preventive Health and Health Services Block Grant to Address Social Determinants of Health to Advance Health Equity.

Frazier, Cassandra M. ;

Mumford, Karen

March 25, 2025 | Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3

State public health departments use federal funding to examine and address social determinants of health (SDOH) within their communities to improve health and advance health equity. Yet, most federal funding is categorical (ie, funding used for a specific program or narrow purpose), which can create barriers to addressing social and structural driv ...

10/10/2026

Supporting Files

Title : The Use of the CDC Preventive Health and Health Services Block Grant to Address Social Determinants of Health to Advance Health Equity. Personal Author(s) : Frazier, Cassandra M.;Mumford, Karen;McMillan, Hannah;Carlin, Maggie;Peterman, Emily;Lindan, Krysia; Published Date : March 25, 2025 Pages in Document : 428-439 (18 pdf pages) Source : Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3 DOI : https://doi.org/10.1097/PHH.0000000000002073 Journal Title : Journal of Public Health Management and Practice: JPHMP
Frazier, C. M., Mumford, K., McMillan, H., Carlin, M., Peterman, E., & Lindan, K. (2025). The Use of the CDC Preventive Health and Health Services Block Grant to Address Social Determinants of Health to Advance Health Equity. Journal of Public Health Management and Practice: JPHMP, 31(3). https://doi.org/10.1097/PHH.0000000000002073

Frazier, Cassandra M., Karen Mumford, Hannah McMillan, Maggie Carlin, Emily Peterman, and Krysia Lindan. "The Use of the CDC Preventive Health and Health Services Block Grant to Address Social Determinants of Health to Advance Health Equity." Journal of Public Health Management and Practice: JPHMP 31, no. 3 (2025). https://doi.org/10.1097/PHH.0000000000002073.

Frazier, Cassandra M., et al. "The Use of the CDC Preventive Health and Health Services Block Grant to Address Social Determinants of Health to Advance Health Equity." Journal of Public Health Management and Practice: JPHMP, vol. 31, no. 3, 2025. Stacks. https://doi.org/10.1097/PHH.0000000000002073.
Export RIS Citation Information. TY - Journal Article AU - Frazier, Cassandra M. AU - Mumford, Karen AU - McMillan, Hannah AU - Carlin, Maggie AU - Peterman, Emily AU - Lindan, Krysia AB - State public health departments use federal funding to examine and address social determinants of health (SDOH) within their communities to improve health and advance health equity. Yet, most federal funding is categorical (ie, funding used for a specific program or narrow purpose), which can create barriers to addressing social and structural drivers of inequity. The Preventive Health and Health Services Block Grant (PHHS Block Grant) is a flexible funding mechanism that provides health departments the latitude to identify and fund initiatives that address local public health needs. It is unclear, however, to what extent health departments use this flexible resource to incorporate SDOH into their programs. AB - Cross-sectional, descriptive analysis of state health department PHHS Block Grant program administrative data. AB - This study examined PHHS Block Grant budgets and workplans for the federal Fiscal Year 2021 to assess whether state health departments aligned their grant-funded program with the national objectives associated with the Healthy People 2030 SDOH Framework. AB - Forty-seven states and the District of Columbia were included in this study. AB - Percent of states that used PHHS Block Grant funds to address SDOH; proportion of funding allocated to address SDOH; percentage of programs that addressed SDOH. AB - Three-fourths (75%) of states allocated funds to 97 programs aligning with at least 1 Healthy People 2030 SDOH-related objective. Fifty of the programs were fully or primarily funded by the PHHS Block Grant. Results also show that as the states' PHHS Block Grant funding level increased so did the percent of states that allocated funding toward SDOH programs. AB - This study shows that state health departments are using the PHHS Block Grant to address SDOH, and that the grant plays an important funding role for these programs. States are incorporating the grant into their funding strategies to address SDOH. AB - Author manuscript AN - cdc:261980 C4 - PMC11932783 DO - https://doi.org/10.1097/PHH.0000000000002073 IS - 3 J2 - Journal of Public Health Management and Practice: JPHMP KW - Preventive Health Services KW - Cross-Sectional Studies KW - Financing, Government KW - Public Health KW - Health Equity KW - Social Determinants of Health KW - Humans KW - Centers for Disease Control and Prevention, U.S. KW - block grants KW - evaluation KW - flexible funding KW - health equity KW - social determinants of health KW - Humans KW - Social Determinants of Health KW - Health Equity KW - Cross-Sectional Studies KW - Centers for Disease Control and Prevention, U.S. KW - Preventive Health Services KW - Financing, Government KW - Public Health LA - eng PY - 2025 T2 - Journal of Public Health Management and Practice: JPHMP T2 - Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3 TI - The Use of the CDC Preventive Health and Health Services Block Grant to Address Social Determinants of Health to Advance Health Equity. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261980 ER -
Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data.

Hwang, Christina S. ;

Montgomery, Martha P.

March 25, 2025 | Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3

Laboratory-based hepatitis C virus (HCV) clearance cascades are an important tool for health departments to track progress toward HCV elimination, but a laboratory-based definition of HCV clearance has not yet been validated.To compare agreement between a laboratory-based HCV clearance definition with a clinical cure definition.Observational.New Yo ...

10/10/2026

Supporting Files

Title : Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data. Personal Author(s) : Hwang, Christina S.;Montgomery, Martha P.;Diaz Munoz, Diana I.;Yin, Shaoman;Teshale, Eyasu H.;Bocour, Angelica; Published Date : March 25, 2025 Pages in Document : 360-367 (17 pdf pages) Source : Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3 DOI : https://doi.org/10.1097/PHH.0000000000002077 Journal Title : Journal of Public Health Management and Practice: JPHMP
Hwang, C. S., Montgomery, M. P., Diaz Munoz, D. I., Yin, S., Teshale, E. H., & Bocour, A. (2025). Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data. Journal of Public Health Management and Practice: JPHMP, 31(3). https://doi.org/10.1097/PHH.0000000000002077

Hwang, Christina S., Martha P. Montgomery, Diana I. Diaz Munoz, Shaoman Yin, Eyasu H. Teshale, and Angelica Bocour. "Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data." Journal of Public Health Management and Practice: JPHMP 31, no. 3 (2025). https://doi.org/10.1097/PHH.0000000000002077.

Hwang, Christina S., et al. "Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data." Journal of Public Health Management and Practice: JPHMP, vol. 31, no. 3, 2025. Stacks. https://doi.org/10.1097/PHH.0000000000002077.
Export RIS Citation Information. TY - Journal Article AU - Hwang, Christina S. AU - Montgomery, Martha P. AU - Diaz Munoz, Diana I. AU - Yin, Shaoman AU - Teshale, Eyasu H. AU - Bocour, Angelica AB - Laboratory-based hepatitis C virus (HCV) clearance cascades are an important tool for health departments to track progress toward HCV elimination, but a laboratory-based definition of HCV clearance has not yet been validated. AB - To compare agreement between a laboratory-based HCV clearance definition with a clinical cure definition. AB - Observational. AB - New York City Department of Health and Mental Hygiene HCV surveillance system data and New York City hepatitis C linkage-to-care program data. AB - Linkage-to-care program participants who were diagnosed with hepatitis C and enrolled in the linkage-to-care program from July 1, 2016, through June 30, 2020. AB - Percent agreement between a laboratory-based HCV clearance definition (surveillance system) and a clinical cure definition (program data). AB - Among 591 program participants with known treatment outcome, the laboratory-based HCV clearance definition and clinical cure definition were concordant in 573 cases (97%). AB - A laboratory-based HCV clearance definition based on public health surveillance data can be a reliable source for monitoring HCV elimination. AB - Author manuscript AN - cdc:261979 C4 - PMC11932781 DO - https://doi.org/10.1097/PHH.0000000000002077 IS - 3 J2 - Journal of Public Health Management and Practice: JPHMP KW - Female KW - Hepatitis C KW - Male KW - Humans KW - Population Surveillance KW - Middle Aged KW - Adult KW - Hepacivirus KW - continuity of patient care KW - data systems KW - hepatitis C KW - patient navigation KW - public health surveillance KW - Adult KW - Female KW - Humans KW - Male KW - Middle Aged KW - Hepacivirus KW - Hepatitis C KW - Population Surveillance LA - eng PY - 2025 T2 - Journal of Public Health Management and Practice: JPHMP T2 - Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3 TI - Validation of a Simplified Laboratory-Based HCV Clearance Definition Using New York City Hepatitis C Program and Surveillance Data. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261979 ER -
Characteristics of Aircrew Who Flew While Infectious With Mpox During the 2022 Multi-country Mpox Outbreak, United States, May 10-September 30, 2022.

Roy, Sheila ;

Gertz, Alida M.

December 10, 2024 | Journal of Travel Medicine, 2024, v. 31, no. 8

Prior to 2022, mpox clade II cases in the United States occurred only in travellers from endemic countries or through exposure to imported animals.1 Human-to-human transmission of mpox during the global 2022 outbreak,2 which involved clade IIb, was primarily associated with sexual contact. In response to this outbreak, the U.S. Centers for Disease ...

10/10/2026

Supporting Files

Title : Characteristics of Aircrew Who Flew While Infectious With Mpox During the 2022 Multi-country Mpox Outbreak, United States, May 10-September 30, 2022. Personal Author(s) : Roy, Sheila;Gertz, Alida M.;Minhaj, Faisal S;Akinkugbe, Olubunmi;Delea, Kristin C.;Lumpkin-Knighten, Antresa;Mase, Sundari R.;Alvarado-Ramy, Francisco;Brown, Clive;Gearhart, Shannon L.; Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : December 10, 2024 Pages in Document : 6 pdf pages Source : Journal of Travel Medicine, 2024, v. 31, no. 8 DOI : https://doi.org/10.1093/jtm/taae135 Journal Title : Journal of Travel Medicine
Roy, S., Gertz, A. M., Minhaj, F. S., Akinkugbe, O., Delea, K. C., Lumpkin-Knighten, A., Mase, S. R., Alvarado-Ramy, F., Brown, C., & Gearhart, S. L. (2024). Characteristics of Aircrew Who Flew While Infectious With Mpox During the 2022 Multi-country Mpox Outbreak, United States, May 10-September 30, 2022. Journal of Travel Medicine, 31(8). https://doi.org/10.1093/jtm/taae135

Roy, Sheila, Alida M. Gertz, Faisal S Minhaj, Olubunmi Akinkugbe, Kristin C. Delea, Antresa Lumpkin-Knighten, Sundari R. Mase, Francisco Alvarado-Ramy, Clive Brown, and Shannon L. Gearhart. "Characteristics of Aircrew Who Flew While Infectious With Mpox During the 2022 Multi-country Mpox Outbreak, United States, May 10-September 30, 2022." Journal of Travel Medicine 31, no. 8 (2024). https://doi.org/10.1093/jtm/taae135.

Roy, Sheila, et al. "Characteristics of Aircrew Who Flew While Infectious With Mpox During the 2022 Multi-country Mpox Outbreak, United States, May 10-September 30, 2022." Journal of Travel Medicine, vol. 31, no. 8, 2024. Stacks. https://doi.org/10.1093/jtm/taae135.
Export RIS Citation Information. TY - Journal Article AU - Roy, Sheila AU - Gertz, Alida M. AU - Minhaj, Faisal S AU - Akinkugbe, Olubunmi AU - Delea, Kristin C. AU - Lumpkin-Knighten, Antresa AU - Mase, Sundari R. AU - Alvarado-Ramy, Francisco AU - Brown, Clive AU - Gearhart, Shannon L. A2 - Centers for Disease Control and Prevention (U.S.) AB - Prior to 2022, mpox clade II cases in the United States occurred only in travellers from endemic countries or through exposure to imported animals.1 Human-to-human transmission of mpox during the global 2022 outbreak,2 which involved clade IIb, was primarily associated with sexual contact. In response to this outbreak, the U.S. Centers for Disease Control and Prevention (CDC) initially recommended aircraft contact investigations (CIs) when the CDC was notified of passengers or aircrew who were infectious with mpox during air travel.3 If the infected person was a crew member, passengers were not considered at elevated risk due to limited exposure time. Other aircrew members were considered to be at increased risk due to the potential for longer duration (≥3 h) of exposure in close proximity (within 6 ft) (direct CDC communication to airlines via the Federal Aviation Administration). AB - Published data on aircrew who travelled while infectious with mpox are limited. Among 13 of the 44 aircrew previously identified and included in a recent Morbidity and Mortality Weekly Report (MMWR), no aircraft contacts were reported as developing mpox following exposure, based on aggregate health department (HD) outcome reporting.3 The current analysis characterized clinical characteristics of- and in-flight infection control measures taken by aircrew who travelled on U.S. domestic and inbound international commercial flights while infectious with mpox. AB - Author manuscript AN - cdc:261978 C4 - PMC11973468 DO - https://doi.org/10.1093/jtm/taae135 IS - 8 J2 - Journal of Travel Medicine KW - Air Travel KW - Infection Control KW - Mpox (monkeypox) KW - Communication KW - Animals KW - Morbidity KW - Aircraft KW - Disease Outbreaks KW - Contact Tracing KW - Humans KW - Aviation KW - Humans KW - Animals KW - Air Travel KW - Contact Tracing KW - Mpox (monkeypox) KW - Infection Control KW - Communication KW - Morbidity KW - Disease Outbreaks KW - Aircraft KW - Aviation LA - eng PY - 2024 T2 - Journal of Travel Medicine T2 - Journal of Travel Medicine, 2024, v. 31, no. 8 TI - Characteristics of Aircrew Who Flew While Infectious With Mpox During the 2022 Multi-country Mpox Outbreak, United States, May 10-September 30, 2022. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261978 ER -
Assessment of Public Health Impact of 20 Non-Research HIV Demonstration Projects by Use of the CDC Science Impact Framework, United States, 2018-2022.

Beltrami, John ;

Carree, Tamara

March 25, 2025 | Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3

Compared with traditional measures of scientific impact, the CDC Science Impact Framework more broadly, directly, and quickly assesses impact of public health science. For 20 CDC-funded HIV prevention projects that were conducted during 2018-2022, health departments documented impact, based on CDC Science Impact Framework domains: Disseminating Sci ...

10/10/2026

Supporting Files

Title : Assessment of Public Health Impact of 20 Non-Research HIV Demonstration Projects by Use of the CDC Science Impact Framework, United States, 2018-2022. Personal Author(s) : Beltrami, John;Carree, Tamara;Spikes, Pilgrim;Mulatu, Mesfin S.;Ajoku, Sophia;Dunbar, Erica; Published Date : March 25, 2025 Pages in Document : E154-E158 (9 pdf pages) Source : Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3 DOI : https://doi.org/10.1097/PHH.0000000000002074 Journal Title : Journal of Public Health Management and Practice: JPHMP
Beltrami, J., Carree, T., Spikes, P., Mulatu, M. S., Ajoku, S., & Dunbar, E. (2025). Assessment of Public Health Impact of 20 Non-Research HIV Demonstration Projects by Use of the CDC Science Impact Framework, United States, 2018-2022. Journal of Public Health Management and Practice: JPHMP, 31(3). https://doi.org/10.1097/PHH.0000000000002074

Beltrami, John, Tamara Carree, Pilgrim Spikes, Mesfin S. Mulatu, Sophia Ajoku, and Erica Dunbar. "Assessment of Public Health Impact of 20 Non-Research HIV Demonstration Projects by Use of the CDC Science Impact Framework, United States, 2018-2022." Journal of Public Health Management and Practice: JPHMP 31, no. 3 (2025). https://doi.org/10.1097/PHH.0000000000002074.

Beltrami, John, et al. "Assessment of Public Health Impact of 20 Non-Research HIV Demonstration Projects by Use of the CDC Science Impact Framework, United States, 2018-2022." Journal of Public Health Management and Practice: JPHMP, vol. 31, no. 3, 2025. Stacks. https://doi.org/10.1097/PHH.0000000000002074.
Export RIS Citation Information. TY - Journal Article AU - Beltrami, John AU - Carree, Tamara AU - Spikes, Pilgrim AU - Mulatu, Mesfin S. AU - Ajoku, Sophia AU - Dunbar, Erica AB - Compared with traditional measures of scientific impact, the CDC Science Impact Framework more broadly, directly, and quickly assesses impact of public health science. For 20 CDC-funded HIV prevention projects that were conducted during 2018-2022, health departments documented impact, based on CDC Science Impact Framework domains: Disseminating Science, Creating Awareness, Catalyzing Action, Effecting Change , and Shaping the Future . Health departments reported 282 impacts: the most common were new partnerships (n = 17, Catalyzing Action ), capacity building (n = 16, Effecting Change ), new projects or initiatives begun (n = 15, Shaping the Future ), new collaborations (n = 14, Catalyzing Action ), improved program (n = 13, Shaping the Future ), new guidelines or practices (n = 13, Effecting Change ), and informed persons affected by work (n = 13, Creating Awareness ). Health departments documented substantial impact with a simple, timely, and broad approach. Demonstrating impact is important for community-based organizations, funders, and others interested in public health and helps them better understand the value of public health. AB - Author manuscript AN - cdc:261977 C4 - PMC11932775 DO - https://doi.org/10.1097/PHH.0000000000002074 IS - 3 J2 - Journal of Public Health Management and Practice: JPHMP KW - Health Impact Assessment KW - Public Health KW - Humans KW - Centers for Disease Control and Prevention, U.S. KW - HIV Infections KW - HIV prevention KW - program science KW - public health impact KW - Humans KW - Centers for Disease Control and Prevention, U.S. KW - HIV Infections KW - Public Health KW - Health Impact Assessment LA - eng PY - 2025 T2 - Journal of Public Health Management and Practice: JPHMP T2 - Journal of Public Health Management and Practice: JPHMP, 2025, v. 31, no. 3 TI - Assessment of Public Health Impact of 20 Non-Research HIV Demonstration Projects by Use of the CDC Science Impact Framework, United States, 2018-2022. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261977 ER -
Genomic Cluster Formation Among Invasive Group a Streptococcal Infections in the USA: a Whole-genome Sequencing and Population-based Surveillance Study.

Li, Yuan ;

Rivers, Joy

December 2024 | The Lancet. Microbe, 2024, v. 5, no. 12

Clusters of invasive group A streptococcal (iGAS) infection, linked to genomically closely related group A streptococcal (GAS) isolates (referred to as genomic clusters), pose public health threats, and are increasingly identified through whole-genome sequencing (WGS) analysis. In this study, we aimed to assess the risk of genomic cluster formation ...

10/10/2026

Supporting Files

Title : Genomic Cluster Formation Among Invasive Group a Streptococcal Infections in the USA: a Whole-genome Sequencing and Population-based Surveillance Study. Personal Author(s) : Li, Yuan;Rivers, Joy;Mathis, Saundra;Li, Zhongya;Chochua, Sopio;Metcalf, Benjamin J;Beall, Bernard;McGee, Lesley; Published Date : December 2024 Pages in Document : 100927 (19 pdf pages) Source : The Lancet. Microbe, 2024, v. 5, no. 12 DOI : https://doi.org/10.1016/S2666-5247(24)00169-1 Journal Title : The Lancet. Microbe
Li, Y., Rivers, J., Mathis, S., Li, Z., Chochua, S., Metcalf, B. J., Beall, B., & McGee, L. (2024). Genomic Cluster Formation Among Invasive Group a Streptococcal Infections in the USA: a Whole-genome Sequencing and Population-based Surveillance Study. The Lancet. Microbe, 5(12). https://doi.org/10.1016/S2666-5247(24)00169-1

Li, Yuan, Joy Rivers, Saundra Mathis, Zhongya Li, Sopio Chochua, Benjamin J Metcalf, Bernard Beall, and Lesley McGee. "Genomic Cluster Formation Among Invasive Group a Streptococcal Infections in the USA: a Whole-genome Sequencing and Population-based Surveillance Study." The Lancet. Microbe 5, no. 12 (2024). https://doi.org/10.1016/S2666-5247(24)00169-1.

Li, Yuan, et al. "Genomic Cluster Formation Among Invasive Group a Streptococcal Infections in the USA: a Whole-genome Sequencing and Population-based Surveillance Study." The Lancet. Microbe, vol. 5, no. 12, 2024. Stacks. https://doi.org/10.1016/S2666-5247(24)00169-1.
Export RIS Citation Information. TY - Journal Article AU - Li, Yuan AU - Rivers, Joy AU - Mathis, Saundra AU - Li, Zhongya AU - Chochua, Sopio AU - Metcalf, Benjamin J AU - Beall, Bernard AU - McGee, Lesley AB - Clusters of invasive group A streptococcal (iGAS) infection, linked to genomically closely related group A streptococcal (GAS) isolates (referred to as genomic clusters), pose public health threats, and are increasingly identified through whole-genome sequencing (WGS) analysis. In this study, we aimed to assess the risk of genomic cluster formation among iGAS cases not already part of existing genomic clusters. AB - In this WGS and population-based surveillance study, we analysed iGAS case isolates from the Active Bacterial Core surveillance (ABCs), which is part of the US Centers for Disease Control and Prevention's Emerging Infections Program, in ten US states from Jan 1, 2015, to Dec 31, 2019. We included all residents in ABCs sites with iGAS infections meeting the case definition and excluded non-conforming GAS infections and cases with whole-genome assemblies of the isolate containing fewer than 1·5 million total bases or more than 150 contigs. For iGAS cases we collected basic demographics, underlying conditions, and risk factors for infection from medical records, and for isolates we included emm types, antimicrobial resistance, and presence of virulence-related genes. Two iGAS cases were defined as genomically clustered if their isolates differed by three or less single-nucleotide variants. An iGAS case not clustered with any previous cases at the time of detection, with a minimum trace-back time of 1 year, was defined as being at risk of cluster formation. We monitored each iGAS case at risk for a minimum of 1 year to identify any cluster formation event, defined as the detection of a subsequent iGAS case clustered with the case at risk. We used the Kaplan-Meier method to estimate the cumulative incidence of cluster formation events over time. We used Cox regression to assess associations between features of cases at risk upon detection and subsequent cluster formation. We developed a random survival forest machine-learning model based on a derivation cohort (random selection of 50% of cases at risk) to predict cluster formation risk. This model was validated using a validation cohort consisting of the remaining 50% of cases at risk. AB - We identified 2764 iGAS cases at risk from 2016 to 2018, of which 656 (24%) formed genomic clusters by the end of 2019. Overall, the cumulative incidence of cluster formation was 0·057 (95% CI 0·048-0·066) at 30 days after detection, 0·12 (0·11-0·13) at 90 days after detection, and 0·16 (0·15-0·18) at 180 days after detection. A higher risk of cluster formation was associated with emm type (adjusted hazard ratio as compared with emm89 was 2·37 [95% CI 1·71-3·30] for emm1, 2·72 [1·82-4·06] for emm3, 2·28 [1·49-3·51] for emm6, 1·47 [1·05-2·06] for emm12, and 2·21 [1·38-3·56] for emm92), homelessness (1·42 [1·01-1·99]), injection drug use (2·08 [1·59-2·72]), residence in a long-term care facility (1·78 [1·29-2·45]), and the autumn-winter season (1·34 [1·14-1·57]) in multivariable Cox regression analysis. The machine-learning model stratified the validation cohort (n=1382) into groups at low (n=370), moderate (n=738), and high (n=274) risk. The 90-day risk of cluster formation was 0·03 (95% CI 0·01-0·05) for the group at low risk, 0·10 (0·08-0·13) for the group at moderate risk, and 0·21 (0·17-0·25) for the group at high risk. These results were consistent with the cross-validation outcomes in the derivation cohort. AB - Using population-based surveillance data, we found that pathogen, host, and environment factors of iGAS cases were associated with increased likelihood of subsequent genomic cluster formation. Groups at high risk were consistently identified by a predictive model which could inform prevention strategies, although future work to refine the model, incorporating other potential risk factors such as host contact patterns and immunity to GAS, is needed to improve its predictive performance. AB - Centers for Disease Control and Prevention. AB - Author manuscript AN - cdc:261976 C4 - PMC11771477 DO - https://doi.org/10.1016/S2666-5247(24)00169-1 IS - 12 J2 - The Lancet. Microbe KW - Adolescent KW - Female KW - Streptococcal Infections KW - Aged KW - Population Surveillance KW - Young Adult KW - Multigene Family KW - Child KW - Aged, 80 and over KW - Streptococcus pyogenes KW - Risk Factors KW - Infant KW - Male KW - Middle Aged KW - Humans KW - Child, Preschool KW - Anti-Bacterial Agents KW - Adult KW - Whole Genome Sequencing KW - Genome, Bacterial KW - Humans KW - Streptococcus pyogenes KW - Streptococcal Infections KW - Whole Genome Sequencing KW - Female KW - Male KW - Middle Aged KW - Adult KW - Aged KW - Child KW - Adolescent KW - Genome, Bacterial KW - Child, Preschool KW - Young Adult KW - Infant KW - Population Surveillance KW - Risk Factors KW - Multigene Family KW - Aged, 80 and over KW - Anti-Bacterial Agents LA - eng PY - 2024 T2 - The Lancet. Microbe T2 - The Lancet. Microbe, 2024, v. 5, no. 12 TI - Genomic Cluster Formation Among Invasive Group a Streptococcal Infections in the USA: a Whole-genome Sequencing and Population-based Surveillance Study. VL - 5 UR - https://stacks.cdc.gov/view/cdc/261976 ER -
Cost-Effectiveness of Mandating Calorie Labels on Prepared Foods in Supermarkets.

Grummon, Anna H. ;

Barrett, Jessica L.

February 2025 | American Journal of Preventive Medicine, 2025, v. 68, no. 2

The U.S. has required chain food establishments-including supermarkets-to display calorie labels on prepared (i.e., ready-to-eat) foods since 2018. Implementation of this supermarket calorie labeling policy reduced purchases of prepared foods from supermarkets, but it remains unknown whether the policy is cost-effective.In 2023-2024, this study app ...

10/10/2026

Supporting Files

Title : Cost-Effectiveness of Mandating Calorie Labels on Prepared Foods in Supermarkets. Personal Author(s) : Grummon, Anna H.;Barrett, Jessica L.;Block, Jason P.;McCulloch, Stephanie;Bolton, Amy;Dupuis, Roxanne;Petimar, Joshua;Gortmaker, Steven L.; Published Date : February 2025 Pages in Document : 300-310 (16 pdf pages) Source : American Journal of Preventive Medicine, 2025, v. 68, no. 2 DOI : https://doi.org/10.1016/j.amepre.2024.10.007 Journal Title : American Journal of Preventive Medicine
Grummon, A. H., Barrett, J. L., Block, J. P., McCulloch, S., Bolton, A., Dupuis, R., Petimar, J., & Gortmaker, S. L. (2025). Cost-Effectiveness of Mandating Calorie Labels on Prepared Foods in Supermarkets. American Journal of Preventive Medicine, 68(2). https://doi.org/10.1016/j.amepre.2024.10.007

Grummon, Anna H., Jessica L. Barrett, Jason P. Block, Stephanie McCulloch, Amy Bolton, Roxanne Dupuis, Joshua Petimar, and Steven L. Gortmaker. "Cost-Effectiveness of Mandating Calorie Labels on Prepared Foods in Supermarkets." American Journal of Preventive Medicine 68, no. 2 (2025). https://doi.org/10.1016/j.amepre.2024.10.007.

Grummon, Anna H., et al. "Cost-Effectiveness of Mandating Calorie Labels on Prepared Foods in Supermarkets." American Journal of Preventive Medicine, vol. 68, no. 2, 2025. Stacks. https://doi.org/10.1016/j.amepre.2024.10.007.
Export RIS Citation Information. TY - Journal Article AU - Grummon, Anna H. AU - Barrett, Jessica L. AU - Block, Jason P. AU - McCulloch, Stephanie AU - Bolton, Amy AU - Dupuis, Roxanne AU - Petimar, Joshua AU - Gortmaker, Steven L. AB - The U.S. has required chain food establishments-including supermarkets-to display calorie labels on prepared (i.e., ready-to-eat) foods since 2018. Implementation of this supermarket calorie labeling policy reduced purchases of prepared foods from supermarkets, but it remains unknown whether the policy is cost-effective. AB - In 2023-2024, this study applied the Childhood Obesity Intervention Cost-Effectiveness Study (CHOICES) microsimulation model to estimate the effects of the supermarket calorie labeling policy on health, costs, and cost-effectiveness over 10 years (2018-2027) for the U.S. AB - The model projected benefits overall and among racial, ethnic, and income subgroups. Sensitivity analyses varied assumptions about the extent to which consumers replace calorie reductions from prepared foods with calories from other sources (i.e., caloric compensation). AB - From 2018-2027, the supermarket calorie labeling policy was projected to save $348 million in healthcare costs (95% Uncertainty Interval [UI]=$263, $426 million), prevent 21,700 cases of obesity (95% UI: 18,200-25,400), including 3,890 cases of childhood obesity (95% UI=2,680, 5,120), and lead to 15,100 quality-adjusted life years (QALYs) gained across the U.S. population (95% UI=10,900, 20,500). The policy was projected to prevent cases of obesity and childhood obesity across all racial, ethnic, and income groups. The policy was projected to be cost-saving when assuming low and moderate caloric compensation and cost-effective when assuming very high caloric compensation. AB - A policy requiring calorie labels on prepared foods in supermarkets was projected to be cost-saving or cost-effective and lead to reductions in obesity across all racial, ethnic, and income groups. AB - Author manuscript AN - cdc:261975 C4 - PMC11757065 DO - https://doi.org/10.1016/j.amepre.2024.10.007 IS - 2 J2 - American Journal of Preventive Medicine KW - Child KW - Fast Foods KW - Food Markets KW - Pediatric Obesity KW - Energy Intake KW - Food Labeling KW - Cost-Benefit Analysis KW - Humans KW - Nutrition Policy KW - Humans KW - Food Labeling KW - Cost-Benefit Analysis KW - Pediatric Obesity KW - Food Markets KW - Energy Intake KW - Child KW - Fast Foods KW - Nutrition Policy LA - eng PY - 2025 T2 - American Journal of Preventive Medicine T2 - American Journal of Preventive Medicine, 2025, v. 68, no. 2 TI - Cost-Effectiveness of Mandating Calorie Labels on Prepared Foods in Supermarkets. VL - 68 UR - https://stacks.cdc.gov/view/cdc/261975 ER -
Low Social Support is Associated With Postpartum Depression Symptoms Among Illinois Postpartum Women.

Holicky, Abigail ;

Horne, Ashley

June 2025 | Birth (Berkeley, Calif.), 2025, v. 52, no. 2

Postpartum depression (PPD) occurs after delivery, with severity and onset varying by individual. Women with low social support may be at higher risk for PPD. This study examined the association between social support and self-reported postpartum depression symptoms (PDS) among Illinois postpartum women.Using 2016-2020 data from the Illinois Pregna ...

10/10/2026

Supporting Files

Title : Low Social Support is Associated With Postpartum Depression Symptoms Among Illinois Postpartum Women. Personal Author(s) : Holicky, Abigail;Horne, Ashley;Bennett, Amanda C.; Published Date : June 2025 Pages in Document : 320-328 (17 pdf pages) Source : Birth (Berkeley, Calif.), 2025, v. 52, no. 2 DOI : https://doi.org/10.1111/birt.12889 Journal Title : Birth (Berkeley, Calif.)
Holicky, A., Horne, A., & Bennett, A. C. (2025). Low Social Support is Associated With Postpartum Depression Symptoms Among Illinois Postpartum Women. Birth (Berkeley, Calif.), 52(2). https://doi.org/10.1111/birt.12889

Holicky, Abigail, Ashley Horne, and Amanda C. Bennett. "Low Social Support is Associated With Postpartum Depression Symptoms Among Illinois Postpartum Women." Birth (Berkeley, Calif.) 52, no. 2 (2025). https://doi.org/10.1111/birt.12889.

Holicky, Abigail, et al. "Low Social Support is Associated With Postpartum Depression Symptoms Among Illinois Postpartum Women." Birth (Berkeley, Calif.), vol. 52, no. 2, 2025. Stacks. https://doi.org/10.1111/birt.12889.
Export RIS Citation Information. TY - Journal Article AU - Holicky, Abigail AU - Horne, Ashley AU - Bennett, Amanda C. AB - Postpartum depression (PPD) occurs after delivery, with severity and onset varying by individual. Women with low social support may be at higher risk for PPD. This study examined the association between social support and self-reported postpartum depression symptoms (PDS) among Illinois postpartum women. AB - Using 2016-2020 data from the Illinois Pregnancy Risk Assessment Monitoring System (PRAMS) (n = 5886), instrumental support (physical, hands-on support) and partner emotional support were each categorized as high/low and were combined in a composite measure (high = high on both types, moderate = high on one type, and low = low on both types). PDS were self-reported. Crude and adjusted odds ratios (aOR) and 95% confidence intervals (CI) were calculated using logistic regression. AB - Overall, 9.6% (95% CI = 8.8-10.4) of Illinois postpartum women experienced PDS. Of Illinois postpartum women, 63.5% (95% CI = 62.1-64.9) had high composite support, 29.3% (95% CI = 28.0-30.6) had moderate composite support, and 7.1% (95% CI = 6.4-7.9) had low composite support. After adjustment for maternal characteristics, instrumental support, partner emotional support, and a composite measure of support were each significantly associated with PDS. Compared to women with high composite support, women with low composite support had six times the odds of PDS (aOR = 6.1, 95% CI = 4.5-8.2), and women with moderate composite support had nearly three times the odds of PDS (aOR = 2.7, 95% CI = 2.2-3.4). AB - PDS was associated with instrumental support, partner emotional support, and a composite measure of support in Illinois postpartum women. This suggests the importance of addressing social support for postpartum individuals. AB - Author manuscript AN - cdc:261974 C4 - PMC12006437 DO - https://doi.org/10.1111/birt.12889 IS - 2 J2 - Birth (Berkeley, Calif.) KW - Pregnancy KW - Female KW - Postpartum Period KW - Humans KW - Depression, Postpartum KW - Young Adult KW - Self Report KW - Logistic Models KW - Adult KW - Social Support KW - Humans KW - Female KW - Social Support KW - Depression, Postpartum KW - Adult KW - Postpartum Period KW - Pregnancy KW - Young Adult KW - Self Report KW - Logistic Models LA - eng PY - 2025 T2 - Birth (Berkeley, Calif.) T2 - Birth (Berkeley, Calif.), 2025, v. 52, no. 2 TI - Low Social Support is Associated With Postpartum Depression Symptoms Among Illinois Postpartum Women. VL - 52 UR - https://stacks.cdc.gov/view/cdc/261974 ER -
Comparative Efficacy of Advanced Therapies For Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.

Ananthakrishnan, Ashwin N. ;

Murad, M. Hassan

December 2024 | Gastroenterology, 2024, v. 167, no. 7

We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC).We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderat ...

10/10/2026

Supporting Files

Title : Comparative Efficacy of Advanced Therapies For Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Personal Author(s) : Ananthakrishnan, Ashwin N.;Murad, M. Hassan;Scott, Frank I.;Agrawal, Manasi;Haydek, John P.;Limketkai, Berkeley N.;Loftus, Edward V;Singh, Siddharth; Published Date : December 2024 Pages in Document : 1460-1482 (38 pdf pages) Source : Gastroenterology, 2024, v. 167, no. 7 DOI : https://doi.org/10.1053/j.gastro.2024.07.046 Journal Title : Gastroenterology
Ananthakrishnan, A. N., Murad, M. H., Scott, F. I., Agrawal, M., Haydek, J. P., Limketkai, B. N., Loftus, E. V., & Singh, S. (2024). Comparative Efficacy of Advanced Therapies For Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology, 167(7). https://doi.org/10.1053/j.gastro.2024.07.046

Ananthakrishnan, Ashwin N., M. Hassan Murad, Frank I. Scott, Manasi Agrawal, John P. Haydek, Berkeley N. Limketkai, Edward V Loftus, and Siddharth Singh. "Comparative Efficacy of Advanced Therapies For Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis." Gastroenterology 167, no. 7 (2024). https://doi.org/10.1053/j.gastro.2024.07.046.

Ananthakrishnan, Ashwin N., et al. "Comparative Efficacy of Advanced Therapies For Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis." Gastroenterology, vol. 167, no. 7, 2024. Stacks. https://doi.org/10.1053/j.gastro.2024.07.046.
Export RIS Citation Information. TY - Journal Article AU - Ananthakrishnan, Ashwin N. AU - Murad, M. Hassan AU - Scott, Frank I. AU - Agrawal, Manasi AU - Haydek, John P. AU - Limketkai, Berkeley N. AU - Loftus, Edward V AU - Singh, Siddharth AB - We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC). AB - We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderate-to-severe UC, comparing different advanced therapies (tumor necrosis factor antagonists, vedolizumab, sphingosine-1-phosphate receptor modulators, interleukin 12/23 or selective interleukin 23 antagonists, and Janus kinase [JAK] inhibitors) against placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission, and our secondary outcome was endoscopic improvement. We performed a network meta-analysis using a frequentist approach and applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to appraise certainty of evidence. AB - After excluding JAK inhibitors as potential first-line treatment (in accordance with the United States Food and Drug Administration), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab, and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologically naïve patients with moderate-to-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission. With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab, with low- to moderate-certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib, and ustekinumab were ranked highest for achieving remission. AB - Using Grading of Recommendations, Assessment, Development and Evaluation to appraise quality of evidence, this updated network meta-analysis will be used to inform comparative efficacy and positioning of advanced therapies for the treatment of biologic-naïve and biologic-exposed patients with moderate-to-severe UC. AB - Author manuscript AN - cdc:261972 C4 - PMC12148344 DO - https://doi.org/10.1053/j.gastro.2024.07.046 IS - 7 J2 - Gastroenterology KW - Treatment Outcome KW - Randomized Controlled Trials as Topic KW - Colitis, Ulcerative KW - Tumor Necrosis Factor Inhibitors KW - Gastroenterology KW - Gastrointestinal Agents KW - Comparative Effectiveness Research KW - Severity of Illness Index KW - Janus Kinase Inhibitors KW - Remission Induction KW - Humans KW - Antibodies, Monoclonal, Humanized KW - Piperidines KW - Societies, Medical KW - Sphingosine 1 Phosphate Receptor Modulators KW - Positioning KW - biologics KW - guidelines KW - inflammatory bowel diseases KW - comparative effectiveness KW - Humans KW - Antibodies, Monoclonal, Humanized KW - Colitis, Ulcerative KW - Comparative Effectiveness Research KW - Gastroenterology KW - Gastrointestinal Agents KW - Janus Kinase Inhibitors KW - Piperidines KW - Randomized Controlled Trials as Topic KW - Remission Induction KW - Severity of Illness Index KW - Societies, Medical KW - Sphingosine 1 Phosphate Receptor Modulators KW - Treatment Outcome KW - Tumor Necrosis Factor Inhibitors LA - eng PY - 2024 T2 - Gastroenterology T2 - Gastroenterology, 2024, v. 167, no. 7 TI - Comparative Efficacy of Advanced Therapies For Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. VL - 167 UR - https://stacks.cdc.gov/view/cdc/261972 ER -
Role Function in Postmenopausal Women During Aromatase Inhibitor Therapy For Breast Cancer.

Melnyk, Halia ;

Dickson, Victoria Vaughan

June 2026 | Journal of Cancer Survivorship : Research and Practice, 2026, v. 20, no. 3

Few studies have examined aromatase inhibitor therapy relating to role function in breast cancer survivors of working age. Our study sought to identify how pre-therapy sociodemographic and health/treatment-related characteristics, as well as patient-reported symptoms measured every six-months, influence role function during 18 months of AI therapy ...

10/10/2026

Supporting Files

Title : Role Function in Postmenopausal Women During Aromatase Inhibitor Therapy For Breast Cancer. Personal Author(s) : Melnyk, Halia;Dickson, Victoria Vaughan;Bender, Catherine;Yu, Gary;Djukic, Maja;Merriman, John; Published Date : June 2026 Pages in Document : 927-939 (21 pdf pages) Source : Journal of Cancer Survivorship : Research and Practice, 2026, v. 20, no. 3 DOI : https://doi.org/10.1007/s11764-024-01697-x Journal Title : Journal of Cancer Survivorship : Research and Practice
Melnyk, H., Dickson, V. V., Bender, C., Yu, G., Djukic, M., & Merriman, J. (2026). Role Function in Postmenopausal Women During Aromatase Inhibitor Therapy For Breast Cancer. Journal of Cancer Survivorship : Research and Practice, 20(3). https://doi.org/10.1007/s11764-024-01697-x

Melnyk, Halia, Victoria Vaughan Dickson, Catherine Bender, Gary Yu, Maja Djukic, and John Merriman. "Role Function in Postmenopausal Women During Aromatase Inhibitor Therapy For Breast Cancer." Journal of Cancer Survivorship : Research and Practice 20, no. 3 (2026). https://doi.org/10.1007/s11764-024-01697-x.

Melnyk, Halia, et al. "Role Function in Postmenopausal Women During Aromatase Inhibitor Therapy For Breast Cancer." Journal of Cancer Survivorship : Research and Practice, vol. 20, no. 3, 2026. Stacks. https://doi.org/10.1007/s11764-024-01697-x.
Export RIS Citation Information. TY - Journal Article AU - Melnyk, Halia AU - Dickson, Victoria Vaughan AU - Bender, Catherine AU - Yu, Gary AU - Djukic, Maja AU - Merriman, John AB - Few studies have examined aromatase inhibitor therapy relating to role function in breast cancer survivors of working age. Our study sought to identify how pre-therapy sociodemographic and health/treatment-related characteristics, as well as patient-reported symptoms measured every six-months, influence role function during 18 months of AI therapy for early-stage breast cancer. AB - We performed a secondary analysis of longitudinal study data using linear mixed-effects modeling to examine role physical (RP) and role emotional (RE) functioning measured with the Medical Outcome Study Short Form 36 v2. The sample of postmenopausal women (N = 351) consisted of three cohorts: chemotherapy followed by anastrozole (CFAI), anastrozole only (AI only), and non-cancer controls. Our choice of variables and interpretation of findings was theoretically based on the Cancer Survivorship and Work Model. Stepwise backward deletion determined which predictors to include in the final model, accounting for treatment group. AB - Both treatment groups were associated with greater limitations in RP functioning than controls. CFAI had twice the impact on RP compared to AI only. While the RP model displayed significant predictors across sociodemographic, health/treatment, and symptom characteristics, only symptoms were associated with greater limitations in RE functioning. Findings were significant at p < .05. AB - Transitioning from acute to extended survivorship is a critical juncture in which multiple factors place breast cancer survivors at risk of diminished role function. AB - Early interventions to address role function limitations during systemic treatment may lead to better work outcomes and improve the quality of long-term survivorship. AB - Author manuscript AN - cdc:261971 C4 - PMC12008247 DO - https://doi.org/10.1007/s11764-024-01697-x IS - 3 J2 - Journal of Cancer Survivorship : Research and Practice KW - Longitudinal Studies KW - Cancer Survivors KW - Female KW - Postmenopause KW - Aromatase Inhibitors KW - Quality of Life KW - Aged KW - Humans KW - Middle Aged KW - Breast Neoplasms KW - Anastrozole KW - Breast cancer survivorship KW - aromatase inhibitor therapy KW - health-related quality of life (HRQoL) KW - role function KW - everyday and work life participation KW - Humans KW - Female KW - Breast Neoplasms KW - Aromatase Inhibitors KW - Postmenopause KW - Middle Aged KW - Longitudinal Studies KW - Cancer Survivors KW - Aged KW - Anastrozole KW - Quality of Life LA - eng PY - 2026 T2 - Journal of Cancer Survivorship : Research and Practice T2 - Journal of Cancer Survivorship : Research and Practice, 2026, v. 20, no. 3 TI - Role Function in Postmenopausal Women During Aromatase Inhibitor Therapy For Breast Cancer. VL - 20 UR - https://stacks.cdc.gov/view/cdc/261971 ER -
A Scoping Review to Determine if Adverse Human Health Effects Are Associated With Use of Organophosphates For Mosquito Control.

Tai, Zoe ;

Connelly, C. Roxanne

January 2025 | Journal of Medical Entomology, 2025, v. 62, no. 1

Organophosphate insecticides are widely used for adult mosquito control. Although proven effective in reducing mosquito populations and limiting arbovirus transmission, public concern exists regarding potential human health effects associated with organophosphate exposure. The aim of this scoping review was to describe any reported human health con ...

10/10/2026

Supporting Files

Title : A Scoping Review to Determine if Adverse Human Health Effects Are Associated With Use of Organophosphates For Mosquito Control. Personal Author(s) : Tai, Zoe;Connelly, C. Roxanne;Lange, Suzanne Kuczynski;Foley, Nicole;De Leon Rivera, Juan;Lozano, Saul;Nett, Randall J.; Published Date : January 2025 Pages in Document : 8-18 (21 pdf pages) Source : Journal of Medical Entomology, 2025, v. 62, no. 1 DOI : https://doi.org/10.1093/jme/tjae130 Journal Title : Journal of Medical Entomology
Tai, Z., Connelly, C. R., Lange, S. K., Foley, N., De Leon Rivera, J., Lozano, S., & Nett, R. J. (2025). A Scoping Review to Determine if Adverse Human Health Effects Are Associated With Use of Organophosphates For Mosquito Control. Journal of Medical Entomology, 62(1). https://doi.org/10.1093/jme/tjae130

Tai, Zoe, C. Roxanne Connelly, Suzanne Kuczynski Lange, Nicole Foley, Juan De Leon Rivera, Saul Lozano, and Randall J. Nett. "A Scoping Review to Determine if Adverse Human Health Effects Are Associated With Use of Organophosphates For Mosquito Control." Journal of Medical Entomology 62, no. 1 (2025). https://doi.org/10.1093/jme/tjae130.

Tai, Zoe, et al. "A Scoping Review to Determine if Adverse Human Health Effects Are Associated With Use of Organophosphates For Mosquito Control." Journal of Medical Entomology, vol. 62, no. 1, 2025. Stacks. https://doi.org/10.1093/jme/tjae130.
Export RIS Citation Information. TY - Journal Article AU - Tai, Zoe AU - Connelly, C. Roxanne AU - Lange, Suzanne Kuczynski AU - Foley, Nicole AU - De Leon Rivera, Juan AU - Lozano, Saul AU - Nett, Randall J. AB - Organophosphate insecticides are widely used for adult mosquito control. Although proven effective in reducing mosquito populations and limiting arbovirus transmission, public concern exists regarding potential human health effects associated with organophosphate exposure. The aim of this scoping review was to describe any reported human health conditions associated with organophosphates during their use for adult mosquito control in the United States and Canada. Original peer-reviewed articles published in English language journals from 1 January 2000 to 22 May 2024, were obtained by searching from the databases MEDLINE, EMBASE, Agricultural & Environmental Science Collection, CAB Abstracts, and Scopus. The search identified 6,154 screened articles. Following an independent review, 10 studies were identified that described human health conditions associated with organophosphate exposure during adult mosquito control applications. Of the 10 included studies, only two articles were published within the last 11 years (2013 to 22 May 2024). Three types of study design were represented in the included studies: cohort (n = 5), case study (n = 1), and risk assessment (n = 4). The included studies could not determine causality between exposure to adulticides and development of illness or adverse impacts. Exposure to organophosphates did not contribute to an observed increase in metabolic toxicity, hospitalization rates, or self-reported symptoms and exposure. The available and limited evidence indicates that organophosphates can be used safely to control nuisance mosquitoes or mosquitoes that transmit arboviruses. Continued research regarding the human health effects associated with organophosphate applications for adult mosquito control could help evaluate the basis of the public's concerns and inform public health decision-making. AB - Author manuscript AN - cdc:261970 C4 - PMC11808927 DO - https://doi.org/10.1093/jme/tjae130 IS - 1 J2 - Journal of Medical Entomology KW - Animals KW - Organophosphates KW - Humans KW - Mosquito Control KW - Insecticides KW - adulticide KW - ultra-low volume KW - malathion KW - naled KW - integrated mosquito management KW - Humans KW - Organophosphates KW - Insecticides KW - Mosquito Control KW - Animals LA - eng PY - 2025 T2 - Journal of Medical Entomology T2 - Journal of Medical Entomology, 2025, v. 62, no. 1 TI - A Scoping Review to Determine if Adverse Human Health Effects Are Associated With Use of Organophosphates For Mosquito Control. VL - 62 UR - https://stacks.cdc.gov/view/cdc/261970 ER -
Vertical-dominant and Multi-axial Vibration Associated With Heavy Vehicle Operation: Effects on Dynamic Postural Control.

Kia, Kiana ;

Park, Jangho

January 2025 | Applied Ergonomics, 2025, v. 122

Heavy vehicle operators suffer from increased fall risk, potentially due to exposure to whole-body vibration (WBV) that compromises postural control. This study aimed to characterize the relative impacts of multi-axial WBV vs. vertical-dominant WBV on dynamic postural control during sit-to-stand transition and stair descent, following prolonged vib ...

10/10/2026

Supporting Files

Title : Vertical-dominant and Multi-axial Vibration Associated With Heavy Vehicle Operation: Effects on Dynamic Postural Control. Personal Author(s) : Kia, Kiana;Park, Jangho;Chan, Allen;Srinivasan, Divya;Kim, Jeong Ho; Published Date : January 2025 Pages in Document : 104402 (31 pdf pages) Source : Applied Ergonomics, 2025, v. 122 DOI : https://doi.org/10.1016/j.apergo.2024.104402 Journal Title : Applied Ergonomics
Kia, K., Park, J., Chan, A., Srinivasan, D., & Kim, J. H. (2025). Vertical-dominant and Multi-axial Vibration Associated With Heavy Vehicle Operation: Effects on Dynamic Postural Control. Applied Ergonomics, 122. https://doi.org/10.1016/j.apergo.2024.104402

Kia, Kiana, Jangho Park, Allen Chan, Divya Srinivasan, and Jeong Ho Kim. "Vertical-dominant and Multi-axial Vibration Associated With Heavy Vehicle Operation: Effects on Dynamic Postural Control." Applied Ergonomics 122 (2025). https://doi.org/10.1016/j.apergo.2024.104402.

Kia, Kiana, et al. "Vertical-dominant and Multi-axial Vibration Associated With Heavy Vehicle Operation: Effects on Dynamic Postural Control." Applied Ergonomics, vol. 122, 2025. Stacks. https://doi.org/10.1016/j.apergo.2024.104402.
Export RIS Citation Information. TY - Journal Article AU - Kia, Kiana AU - Park, Jangho AU - Chan, Allen AU - Srinivasan, Divya AU - Kim, Jeong Ho AB - Heavy vehicle operators suffer from increased fall risk, potentially due to exposure to whole-body vibration (WBV) that compromises postural control. This study aimed to characterize the relative impacts of multi-axial WBV vs. vertical-dominant WBV on dynamic postural control during sit-to-stand transition and stair descent, following prolonged vibration exposures. We also compared the effectiveness of a standard (single-axial passive suspension) seat with a multi-axial active suspension seat intervention. Vertical-dominant WBV adversely affected dynamic postural control. However, multi-axial WBV had no added adverse effects on postural control compared to vertical-dominant WBV. The multi-axial active suspension system did not outperform the standard seat in mitigating vibration effects on postural control during exposures but led to faster recovery during breaks between exposures. Overall, our results confirmed the negative effects of WBV on dynamic postural control but did not detect any additional negative effects associated with multi-axial WBV when compared to vertical-dominant WBV. AB - Author manuscript AN - cdc:261969 C4 - PMC12486144 DO - https://doi.org/10.1016/j.apergo.2024.104402 J2 - Applied Ergonomics KW - Occupational Exposure KW - Motor Vehicles KW - Postural Balance KW - Female KW - Posture KW - Sitting Position KW - Male KW - Accidental Falls KW - Humans KW - Young Adult KW - Vibration KW - Adult KW - Whole-body vibration KW - Falls KW - Humans KW - Vibration KW - Male KW - Postural Balance KW - Adult KW - Occupational Exposure KW - Female KW - Young Adult KW - Sitting Position KW - Accidental Falls KW - Motor Vehicles KW - Posture LA - eng PY - 2025 T2 - Applied Ergonomics T2 - Applied Ergonomics, 2025, v. 122 TI - Vertical-dominant and Multi-axial Vibration Associated With Heavy Vehicle Operation: Effects on Dynamic Postural Control. VL - 122 UR - https://stacks.cdc.gov/view/cdc/261969 ER -
Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant?

Arendrup, Maiken Cavling ;

Lockhart, Shawn R.

January 2025 | Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025, v. 31, no. 1

Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing, or adoption of a clinical breakpoint that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain co ...

10/10/2026

Supporting Files

Title : Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant? Personal Author(s) : Arendrup, Maiken Cavling;Lockhart, Shawn R.;Wiederhold, Nathan; Published Date : January 2025 Pages in Document : 108-112 (11 pdf pages) Source : Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025, v. 31, no. 1 DOI : https://doi.org/10.1016/j.cmi.2024.10.010 Journal Title : Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Arendrup, M. C., Lockhart, S. R., & Wiederhold, N. (2025). Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant?. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 31(1). https://doi.org/10.1016/j.cmi.2024.10.010

Arendrup, Maiken Cavling, Shawn R. Lockhart, and Nathan Wiederhold. "Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant?." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 31, no. 1 (2025). https://doi.org/10.1016/j.cmi.2024.10.010.

Arendrup, Maiken Cavling, et al. "Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant?." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 31, no. 1, 2025. Stacks. https://doi.org/10.1016/j.cmi.2024.10.010.
Export RIS Citation Information. TY - Journal Article AU - Arendrup, Maiken Cavling AU - Lockhart, Shawn R. AU - Wiederhold, Nathan AB - Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing, or adoption of a clinical breakpoint that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection. AB - Forty C. auris strains from nine U.S. states and ≥3 clades were included. Fourteen MIC data sets were generated using European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.4, Clinical and Laboratory Standards Institute (CLSI) M27Ed4, Etest, and MIC gradient test strip (MTS, Liofilchem) MICs. MICs ≤1 mg/L were classified as susceptible. AB - EUCAST and CLSI amphotericin B MIC testing were robust across the included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar geometric mean (GM)-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest, and MTS strip MICs correlated to the optical density of drug-free control EUCAST wells, suggesting that some isolates grew better than others and that this was associated with MIC. AB - The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggests the current breakpoint leads to random susceptibility classification. AB - Author manuscript AN - cdc:261968 C4 - PMC11931498 DO - https://doi.org/10.1016/j.cmi.2024.10.010 IS - 1 J2 - Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases KW - Candida auris KW - Drug Resistance, Fungal KW - Humans KW - Antifungal Agents KW - Candidiasis KW - Microbial Sensitivity Tests KW - Amphotericin B KW - Amphotericin KW - C. auris KW - Candidiasis KW - Gradient strip KW - MIC KW - Microbroth dilution KW - Reference KW - Amphotericin B KW - Microbial Sensitivity Tests KW - Antifungal Agents KW - Humans KW - Drug Resistance, Fungal KW - Candidiasis KW - Candida auris LA - eng PY - 2025 T2 - Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases T2 - Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025, v. 31, no. 1 TI - Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant? VL - 31 UR - https://stacks.cdc.gov/view/cdc/261968 ER -
Perspectives of Healthcare Providers Around Providing Family Planning Services to Women Living With HIV Attending Six HIV Treatment Clinics in Lusaka, Zambia.

Medley, Amy ;

Aholou, Tiffiany

January 2025 | AIDS Care, 2025, v. 37, no. 1

While international guidelines recommend integration of family planning (FP) and HIV services, limited research has been done to explore how healthcare providers perceive the feasibility and utility of integrated services. To address this gap, we administered a standardized questionnaire to 85 providers from 6 HIV clinics in Lusaka, Zambia, before ...

10/10/2026

Supporting Files

Title : Perspectives of Healthcare Providers Around Providing Family Planning Services to Women Living With HIV Attending Six HIV Treatment Clinics in Lusaka, Zambia. Personal Author(s) : Medley, Amy;Aholou, Tiffiany;Pals, Sherri;Harris, Tiffany G.;Senyana, Brenda;Braaten, Mollie;Kasonde, Prisca;Chisenga, Tina;Mwila, Annie;Mweebo, Keith;Tsiouris, Fatima; Published Date : January 2025 Pages in Document : 43-53 (19 pdf pages) Source : AIDS Care, 2025, v. 37, no. 1 DOI : https://doi.org/10.1080/09540121.2024.2414077 Journal Title : AIDS Care
Medley, A., Aholou, T., Pals, S., Harris, T. G., Senyana, B., Braaten, M., Kasonde, P., Chisenga, T., Mwila, A., Mweebo, K., & Tsiouris, F. (2025). Perspectives of Healthcare Providers Around Providing Family Planning Services to Women Living With HIV Attending Six HIV Treatment Clinics in Lusaka, Zambia. AIDS Care, 37(1). https://doi.org/10.1080/09540121.2024.2414077

Medley, Amy, Tiffiany Aholou, Sherri Pals, Tiffany G. Harris, Brenda Senyana, Mollie Braaten, and Prisca Kasonde, et al.. "Perspectives of Healthcare Providers Around Providing Family Planning Services to Women Living With HIV Attending Six HIV Treatment Clinics in Lusaka, Zambia." AIDS Care 37, no. 1 (2025). https://doi.org/10.1080/09540121.2024.2414077.

Medley, Amy, et al. "Perspectives of Healthcare Providers Around Providing Family Planning Services to Women Living With HIV Attending Six HIV Treatment Clinics in Lusaka, Zambia." AIDS Care, vol. 37, no. 1, 2025. Stacks. https://doi.org/10.1080/09540121.2024.2414077.
Export RIS Citation Information. TY - Journal Article AU - Medley, Amy AU - Aholou, Tiffiany AU - Pals, Sherri AU - Harris, Tiffany G. AU - Senyana, Brenda AU - Braaten, Mollie AU - Kasonde, Prisca AU - Chisenga, Tina AU - Mwila, Annie AU - Mweebo, Keith AU - Tsiouris, Fatima AB - While international guidelines recommend integration of family planning (FP) and HIV services, limited research has been done to explore how healthcare providers perceive the feasibility and utility of integrated services. To address this gap, we administered a standardized questionnaire to 85 providers from 6 HIV clinics in Lusaka, Zambia, before (April-May 2018) and after (May-June 2019) implementing an enhanced model of FP/HIV service integration. We tested for differences in FP knowledge, attitudes and practices between the two time periods with tests appropriate for paired observations. The proportion of providers self-reporting direct provision of contraceptives increased significantly for several methods including oral contraceptives (14% vs. 26%, AB - = 0.03), injectables (9% vs. 25%, AB - < 0.001), implants (2% vs. 13%, AB - = 0.007) and intra-uterine devices (2% vs. 13%, AB - = 0.007). In-depth interviews were also conducted post-integration with 109 providers to solicit their feedback on the benefits and challenges of offering integrated services. While providers were highly supportive of integrated services, they identified several challenges including widespread belief in FP myths among female clients, the need to consult a male partner prior to starting FP, lack of trained staff and space, and frequent stockouts of contraceptives and equipment. Addressing these challenges will be critical in designing future services. AB - Author manuscript AN - cdc:261967 C4 - PMC11980417 DO - https://doi.org/10.1080/09540121.2024.2414077 IS - 1 J2 - AIDS Care KW - Attitude of Health Personnel KW - Health Knowledge, Attitudes, Practice KW - Female KW - Ambulatory Care Facilities KW - Contraception KW - Health Personnel KW - Family Planning Services KW - Surveys and Questionnaires KW - Delivery of Health Care, Integrated KW - Male KW - Middle Aged KW - Humans KW - Adult KW - HIV Infections KW - HIV/AIDS KW - family planning KW - women living with HIV (WLHIV) KW - Zambia KW - SDG 3: Good health and well-being KW - SDG 5: Gender equality KW - Humans KW - Family Planning Services KW - Female KW - HIV Infections KW - Health Personnel KW - Adult KW - Health Knowledge, Attitudes, Practice KW - Surveys and Questionnaires KW - Attitude of Health Personnel KW - Contraception KW - Male KW - Ambulatory Care Facilities KW - Middle Aged KW - Delivery of Health Care, Integrated LA - eng PY - 2025 T2 - AIDS Care T2 - AIDS Care, 2025, v. 37, no. 1 TI - Perspectives of Healthcare Providers Around Providing Family Planning Services to Women Living With HIV Attending Six HIV Treatment Clinics in Lusaka, Zambia. VL - 37 UR - https://stacks.cdc.gov/view/cdc/261967 ER -

Previous Page Previous

281 - 300 / 1970

Next Page Next

Found an issue?

Send us an email at: publishinghd@cdc.gov